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PURPOSE. To determine whether knockdown of Müller cell–derived VEGFA-splice variant,
VEGF164, which is upregulated in the rat retinopathy of prematurity (ROP) model, safely
inhibits intravitreal neovascularization (IVNV).
METHODS. Short hairpin RNAs for VEGF164 (VEGF164.shRNAs) or luciferase.shRNA control
were cloned into lentivectors with CD44 promoters that specifically target Müller cells.
Knockdown efficiency, off-target effects, and specificity were tested in HEK reporter cell lines
that expressed green fluorescent protein (GFP)-tagged VEGF164 or VEGF120 with flow
cytometry or in rat Müller cells (rMC-1) by real-time PCR. In the rat oxygen-induced
retinopathy (OIR) ROP model, pups received 1 lL subretinal lentivector-driven lucifer-
ase.shRNA, VEGFA.shRNA, or VEGF164.shRNA at postnatal day 8 (P8). Analyses at P18 and
P25 included: IVNV and avascular retina (AVA); retinal and serum VEGF (ELISA); density of
phosphorylated VEGFR2 (p-VEGFR2) in lectin-labeled retinal endothelial cells (ECs;
immunohistochemistry); TUNEL staining and thickness of inner nuclear (INL) and outer
nuclear layers (ONL) in retinal cryosections; and pup weight gain.
RESULTS. In HEK reporter and in rMC-1 cells and in comparison to lucifferase.shRNA,
VEGFA.shRNA reduced both VEGF120 and VEGF164, but VEGF164.shRNA only reduced
VEGF164 and not VEGF120. Compared with luciferase.shRNA, VEGFA.shRNA and
VEGF164.shRNA reduced retinal VEGF and IVNV without affecting AVA at P18 and P25. At
P25, VEGF164.shRNA more effectively maintained IVNV inhibition than VEGFA.shRNA.
VEGFA.shRNA and VEGF164.shRNA reduced pVEGFR2 in retinal ECs at P18, but
VEGFA.shRNA increased it at P25. VEGFA.shRNA increased TUNELþ cells at P18 and
decreased ONL thickness at P18 and P25. VEGFA.shRNA and VEGF164.shRNA did not affect
pup weight gain and serum VEGF.
CONCLUSIONS. Short hairpin RNA to Müller cell VEGF164 maintained long-term inhibition of
IVNV and limited cell death compared with shRNA to VEGFA.
Keywords: vascular endothelial growth factor, lentivector, short hairpin RNA, intravitreal
neovascularization, Müller cells
Vascular endothelial growth factor is important in severalangiogenic eye diseases, including AMD,1,2 diabetic reti-
nopathy,3,4 retinal vein occlusion,3 and retinopathy of prema-
turity (ROP).5,6 We previously found that overactivation of
VEGF receptor 2 (VEGFR2) led to disordered developmental
angiogenesis7 in a similar pattern as seen in intravitreal
neovascularization (IVNV) in severe ROP.8 Broad inhibition of
VEGF with an intravitreal neutralizing antibody reduced IVNV
in a rat model of ROP, but also reduced pup growth and serum
VEGF levels.9 To target pathologic effects of VEGFA without
affecting physiologic ones, we localized VEGFA splice variant
mRNAs to cellular retinaldehyde-binding protein (CRALBP)-
labeled Müller cells, RPE, and cells in the ganglion cell layer in
the retina of a rat model of ROP at a time point when total
retinal VEGFA expression was significantly increased compared
with room air-raised pups.10 We created lentivectors that used
CD44 promoters and efficiently drove VEGFA shRNA specifi-
cally in Müller cells when delivered into the subretinal
space.11,12 In the short-term, IVNV was inhibited without
affecting serum VEGFA, pup growth, or retinal apoptosis.12
However, Müller cells also depend on VEGFA for survival13 and
this strategy may potentially have adverse effects. Therefore, in
this study, we created lentivectors with CD44 promoters that
specifically targeted Müller cell-VEGF164, which leads to
pathologic angiogenesis14,15 and which we found to be the
most prevalent splice variant in the ROP model.10 We tested the
hypothesis that the lentivector shRNA to rat VEGF164 in Müller
cells would safely and effectively reduce IVNV compared with
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knockdown of VEGFA or control and also tested efficacy and
retinal cell survival at a later time point in the ROP model. We
found that targeted lentivector delivery of shRNAs to VEGFA or
VEGF164 reduced IVNV, but that shRNA to VEGF164 maintained
long-term inhibition of IVNV and limited cell death compared
with shRNA to VEGFA.
METHODS
Rat Model of ROP (Rat 50/10 OIR Model)
All animal care was in accordance with the Use of Laboratory
Animals and the ARVO Statement for the Use of Animals in
Ophthalmology and Vision Research and approved by the
Institutional Animal Care and Use Committee (IACUC) at the
University of Utah. In the well-described rat oxygen-induced
retinopathy (OIR) model (rat model of ROP),16,17 Sprague-
Dawley (Charles River Laboratories, Inc., Wilmington, MA)
dams and pups are placed into a dual channel/dual gas
controller (OxyCycler; BioSpherix, Ltd., Lacona, NY) within 6
hours of birth, where oxygen is cycled between 50% and 10%
every 24 hours. At postnatal day (P)14, litters were placed into
room air until P18 or P25. Litter size was maintained at 12 to 16
pups. Pup weight was obtained at P8, P18, and P25. Pups were
euthanized by intraperitoneal injection (IP) of ketamine (60
mg/kg) and xylazine (18 mg/kg) followed by IP pentobarbital
(80 mg/kg). For all pups, one eye was processed for flatmount
analysis and the fellow eye for protein or immunohistochem-
istry (IHC).
Construction of Lentivector-Driven shRNA
Short hairpin RNAs targeting rat VEGFA (NM_031836, VEG-
FA.shRNA); rat VEGF164 (AF260425, VEGF164.shRNA); or
nonmammalian gene luciferase (M15077, luciferase.shRNA)
were developed. shRNAs were embedded within a microRNA
(miR-30) context as an efficient method to knock down a
gene.18,19 The shRNA-microRNA30 was each cloned into a
lentiviral transfer vector driven by a CD44 promoter specific to
Müller cells (pFmCD44.1GW) and with multicistronic cotran-
scription of green fluorescent protein (GFP)20 or red fluores-
cent protein (RFP).11 The VEGFA.shRNAs were previously
developed and tested for off-target effects and efficiency.12
Here, we describe methods for lentivectors with VEGF164.shR-
NAs. Knockdown and off-target efficiency was tested in rat
Müller cells (rMC-1; line provided by Vijay Sarthy, Northwest-
ern University, Evanston, IL) and VEGF120 and VEGF164 HEK
reporter cell lines,12 with the goal to choose shRNAs with
better knockdown efficiency in VEGF164 but not VEGF120.
Cell Culture and Assay for In Vitro–Knockdown
Efficiency
Rat Müller cells, VEGF120, and VEGF164 HEK reporter cell lines
were maintained in DMEM/high glucose (Gibco/Life Technol-
ogies, Grand Island, NY) containing 10% fetal bovine serum
(FBS) and 1% penicillin-streptomycin. Both VEGF120 and
VEGF164 HEK reporter cell lines were transfected with plasmid
DNA-pFmCD44.1GW containing VEGF164.shRNA-1 or
VEGF164.shRNA-2 expressed with RFP or an empty vector
without shRNA as control. Forty-eight hours after transfection,
the knockdown efficiency of VEGF164.shRNAs was deter-
mined by flow cytometry of GFP fluorescence in RFP positive
cells. Silencing was calculated as a percentage of GFP to
control vector transfected-cells. The shRNA with better
knockdown efficiency in VEGF164 but not VEGF120 was chosen
for all following experiments and designated VEGF164.shRNA.
rMC-1 cells in 6-well plates (Corning, Inc., Corning, NY) with
80% confluence were infected with lentivirus (5.0 3 106 viral
particles/mL) containing VEGFA.shRNA, VEGF164.shRNA, lu-
ciferase.shRNA, or vehicle without viral infection. After 48
hours, cells were extracted and real-time PCR was performed.
Each condition was performed in triplicate.
Subretinal Injection
At the beginning of P8 (50% oxygen cycle), pups were
anesthetized by IP ketamine (20 mg/kg) and xylazine (2.5 mg/
kg). Subretinal injections were performed by creating an initial
opening beneath the limbus with a 30-gauge needle. One lL of
1 3 109 viral particles/mL (VP/mL) of VEGFA.shRNA,
VEGF164.shRNA, or control luciferase.shRNA was delivered
into the subretinal space using a 33-gauge needle attached to a
syringe (Hamilton Company, Reno, NY). In some pups, 1 lL of
subretinal PBS was used as an additional control. The created
retinal detachments resolved within 24 hours. The same virus
and dose were used in each eye of the same pup. Attempts
were made to represent all lentivector types in each litter and
to inject the same number of pups with each lentivector
preparation in each litter. Pups weighing less than 7 g were not
used and all pups analyzed were within 62 g of mean pup
weight based on overall growth chart.21,22
In Vivo Retinal Imaging
Pupil dilation was achieved with tropicamide (1% solution;
Bausch & Lomb Pharmaceuticals, Inc., Rochester, NY). Genteal
gel (Novartis Pharmaceuticals Corp., East Hanover, NJ) was the
coupling agent for retinal imaging with a commercial
applanation imaging system (Micron III; Phoenix Research
Laboratories, Inc., Pleasanton, CA) and multiple camera
recording software (StreamPix 5; Norpix, Inc., Montreal,
Quebec, Canada). Both GFP and bright field were used for
imaging.
Retinal Flatmount Preparation, Imaging, and
Analysis
After euthanasia, eyes were enucleated, pierced through the
cornea with a 30-gauge needle, placed into freshly made 4%
paraformaldehyde (PFA) containing 10 mM sodium orthovana-
date for 2 hours on ice, and then transferred to PBS. Corneas,
lenses, and vitreous were removed, and retinas were dissected
from the RPE/choroid/sclera. Retinal flatmounts were labeled
using 5 lg/mL AlexaFluor 568 conjugated isolectin GS-IB4 from
Griffonia simplicifolia (Bandeiraea; Molecular Probes, Eugene,
OR) and imaged using an inverted fluorescence microscope
(Olympus IX81; Olympus Corp., Tokyo, Japan).12 Whole retinal
flatmount images were stitched using the scan-slide stitching
function of imaging software (Metamorph version 7.0;
Molecular Devices, Inc., Sunnyvale, CA). The avascular retina
(AVA) and IVNV areas were analyzed by two masked reviewers
and calculated as a percentage of total retinal area for each
flatmount using Java-based imaging software (ImageJ version
1.46; National Institutes of Health, Bethesda, MD).
Cryosection Preparation and Immunofluorescence
Staining and Quantification
Whole eye globes were fixed in 4% PFA containing 10 mM
sodium orthovanadate for 10 minutes. Corneas and lenses were
removed, and posterior eyecups were fixed for another 15
minutes in 4% PFA, then incubated in 30% sucrose/PBS at 48C
overnight, and mounted in optimal cutting temperature
compound (Tissue-Tek; Electron Microscopy Sciences, Hat-
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field, PA). Cryosections (12 lm) were cut sequentially and
stained for immunofluorescence analysis. Cryosections were
incubated with rabbit anti-phosphorylated VEGFR2 (p-VEGFR2
at Y951; Santa Cruz Biotechnology, Santa Cruz, CA) overnight at
48C. After washes, sections were incubated with AlexaFluor 405
conjugated goat anti-rabbit second antibody for p-VEGFR2 and
lectin for 1 hour. Sections stained with only secondary antibody
and DAPI were controls. TUNEL staining was performed per
instructions in the cell death detection kit (In Situ Cell Death
Detection Kit, TMR red; Roche Diagnostics, Indianapolis, IN).
DNase-treated sections were used as positive controls. Images
were captured with confocal microscopy (Olympus IX81;
Olympus Corp.). To determine the effects of knockdown on
retinal VEGFR2 activation in captured images, semiquantitative
assessment of the density of p-VEGFR2 was performed in
sections of retina extending from the ganglion cell layer to lectin
stained choroidal vessels depicting the RPE/choroid layer using
Java-based imaging software (NIH). For p-VEGFR2 in retinal
vessels, the density of p-VEGFR2 colabeling with lectin-stained
ECs of the primary vascular plexus at the junctions between
avascular retina and vascular retina was measured with the
threshold function of the Java-based imaging software (NIH).
TUNEL-positive cells colabeled with tetramethylrhodamine red
(TMR red) and diamino-2-phenylindole (DAPI) were counted in
retinal sections imaged at 34 magnification. Retinal thickness
was measured from ganglion cell to ONL in DAPI-stained
sections captured at 340 magnification using Java-based imaging
software (NIH). In total, six sections taken at 60-lm intervals
from three eyes of three pups in three litters were used for
immunohistochemical analyses.
Retinal Protein Preparation and VEGF ELISA
Retinas were homogenized in modified radio-immunoprecipi-
tation assay buffer containing 2 mM orthovanadate and
protease inhibitors (Roche Diagnostics). Protein concentration
was determined by bicinchocinic acid (BCA) protein assay
(Pierce Biotechnology, Inc., Rockford, IL). Total retinal and
serum VEGF concentration was measured using a commercial
ELISA kit (Quantikine Rat VEGFA RRV00; R&D Systems,
Minneapolis, MN) following manufacturer’s instructions. Se-
rum (50 lL) or 50 lg protein of retinal lysates was used for
each sample, and samples were in duplicate.
Statistical Analysis
Significant differences between treatment groups were deter-
mined with ANOVA and Newman-Keuls multiple comparison
test. For each test, a minimum value of P < 0.05 was
considered statistically significant. Except where indicated
otherwise, at least eight flat mounts, six samples for Western
blot, and four samples for ELISA were analyzed. All samples
were taken from different pups from at least three different
litters. Results are mean 6 SD.
RESULTS
Generation and Knockdown Efficiency of
Lentivector-Driven VEGF164-shRNA
We designed two different shRNAs for the rat VEGF164 coding
sequence (GenBank: AF260425) and cloned each into the
lentivector pFmCD44.1 GW, which contains a CD44 promoter
specific to Müller cells and drives a microRNA30 (miR-30)–
based shRNA cassette and either RFP or GFP. To test
knockdown efficiency of the designed shRNAs, lentivector
plasmids containing either of the two shRNAs and an RFP tag
or an empty vector were transfected into one of two HEK293
reporter cell lines that expressed either GFP-tagged rat
VEGF120 or VEGF164. Green fluorescent protein fluorescence
intensity in RFP-expressed cells containing the shRNAs or
empty vector was read using flow cytometry (Fig. 1A). Neither
FIGURE 1. Generation of lentivector-delivered shRNA for specific knockdown of VEGF164 in Müller cells. HEK reporter cell lines expressed GFP-
tagged VEGF120 or VEGF164 were transfected with RFP-expressed lentivector VEGF164.shRNA plasmids or empty vector without shRNA. (A) Flow
cytometry (fluorescence activated cell sorting [FACS]) of GFP fluorescence. (B) Quantification of percent silencing of VEGF120 and VEGF164 by
VEGF164 shRNAs from FACS analysis. (C) Real-time PCR of mRNA of VEGF120 and VEGF164 in rMC-1 infected without lentivirus (uninfected) or with
lentivector-driven shRNA to luciferase (luc.shRNA), VEGFA (VEGFA.shRNA), or VEGF164 (VEGF164.shRNA). *P < 0.05 and **P < 0.01 versus
luc.shRNA).
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VEGF164.shRNA-1 nor -2 had an effect on knockdown of
VEGF120 (Fig. 1B). Compared with cells transfected with empty
vector, VEGF164.shRNA-2 caused 35% knockdown of VEGF164,
whereas VEGF164.shRNA-1 only caused 15% knockdown of
VEGF164. Therefore, VEGF164.shRNA-2 (designated hereafter
as VEGF164.shRNA) was chosen for later experiments. The
sequence of VEGF164.shRNA was: 5 0-TGCTGTTGACAG
TGAGCGCAGCCAGAAAATCACTGTGAGCTAGTGAAGCCA
CAGATGTAGCTCACAGTGATTTTCTGGCTTTGCCTACTGCCTC
GGA-30. We previously reported how lentivectors targeting rat
Müller cell VEGFA were designed and tested and chose a
VEGFA.shRNA that caused 35% reduction in VEGF120 and 50%
of VEGF164 in HEK reporter cell lines.
12
To test knockdown efficiency and specificity of lentivector-
driven VEGF164.shRNA and VEGFA.shRNA in Müller cells, we
infected rMC-1s, a rat Müller cell line, with lentivectors
containing the CD44 promoter driving GFP and one of the
three different shRNAs (luciferase.shRNA, VEGFA.shRNA,
VEGF164.shRNA) or an uninfected control. After 48 hours,
rMC-1s were analyzed with real-time PCR for VEGF120 or
VEGF164 mRNAs and expressed as fold difference compared
with the mRNA from the uninfected control. There was no
difference in mRNA level of VEGF120 and VEGF164 splice
variants between uninfected and luciferase.shRNA. Compared
with luciferase.shRNA, VEGFA.shRNA reduced expression of
both VEGF120 and VEGF164 (Fig. 1C), whereas only VEGF164
mRNA was reduced in the VEGF164.shRNA group. These
results provide evidence that VEGF164.shRNA specifically
knocked down VEGF164 mRNA and not VEGF120.
Knockdown of VEGF164 Reduced IVNV at P18 and
P25
Images were taken before euthanasia using an applanation
imaging system (Phoenix Research Laboratories, Inc.) to assess
transduction of each of the three lentivectors that had been
delivered as subretinal injections to P8 pup eyes. At P25, GFP
fluorescence demonstrated that approximately 33% of the
retina was transduced by each subretinal injection of
lentivector shRNA and not with the PBS injection (Fig. 2A).
Müller cell specificity was determined by colabeling of GFP and
CRALBP in retinal cryosections (Fig. 2B). To determine
knockdown efficiency of VEGF in vivo, total retina lysates
were analyzed for VEGF by ELISA. Compared with respective
luciferase.shRNA controls at P18 and P25, retinal VEGF was
significantly decreased by treatment with lentivector VEG-
FA.shRNA or VEGF164.shRNA at both time points (Fig. 2C).
VEGFA.shRNA and VEGF164.shRNA each significantly
inhibited IVNV at P18 compared with luciferase.shRNA (Figs.
3A, 3B). At P25, IVNV was significantly reduced in pup eyes
treated with the luciferase.shRNA compared with those treated
at P18. This was anticipated, because IVNV naturally regresses
in the ROP model. At P25, VEGF164.shRNA significantly
inhibited IVNV compared with VEGFA.shRNA, whereas VEG-
FA.shRNA increased IVNV at P25 compared with P18. These
findings suggest that VEGF164.shRNA, but not VEGFA.shRNA,
was superior in maintaining inhibition of IVNV (Figs. 3A, 3B),
and that VEGFA.shRNA-treated eyes had recurrent IVNV.
Neither VEGFA.shRNA nor VEGF164.shRNA had an effect on
AVA at either P18 or P25, compared with luciferase.shRNA
(Figs. 3A, 3C).
VEGFR2 Activation in Retinal ECs After Targeted
VEGFA.shRNA or VEGF164.shRNA
To determine if targeted treatment with VEGFA.shRNA or
VEGF164.shRNA inhibited total retinal VEGFR2 signaling,
densitometry of p-VEGFR2 was measured from the ganglion
cell layer to the RPE/choroid layer in cryosections colabeled
with p-VEGFR2 and lectin (Figs. 4A, 4B). To determine the
effect of VEGFA.shRNA or VEGF164.shRNA on VEGFR2
activation in endothelial cells, lectin and p-VEGFR2 colabeling
FIGURE 2. In vivo analysis of lentivector-delivered shRNA transduction in retina of pups raised in the rat ROP model at P18 and P25 following
subretinal injection at P8. (A) Micron III images show GFP expression in retina of pups following lentivirus injection at P25. (B) GFP expression is
localized with CRALBP-labeled Müller cells in retinal cryosections at P25. (C) ELISA of retinal VEGFA protein at P18 and P25. *P < 0.05. **P < 0.001
versus luc.shRNA at P18. †P < 0.05. ††P < 0.01 versus luc.shRNA at P25.
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was analyzed with densitometry in the cryosections at the
junctions between avascular and vascular retina in the inner
plexus (Figs. 4A, 4C). At P18, neither treatment significantly
inhibited total retinal p-VEGFR2 density (Fig. 4B) compared
with luciferase.shRNA, but VEGFA.shRNA and VEGF164.shRNA
each reduced colabeling of lectin and p-VEGFR2 in the
vascular/avascular junction where IVNV developed (Fig. 4C).
At P25, there was increased p-VEGFR2 labeling in the retina in
both VEGFA and VEGF164.shRNA sections compared with
luciferase.shRNA (Fig. 4B). There was also increased p-VEGFR2
colabeling with endothelial cells in VEGFA.shRNA-treated
sections but not in VEGF164.shRNA-treated ones (Fig. 4C).
VEGFA.shRNA and VEGF164.shRNA Effects on
Retinal Survival, Serum VEGF, and Pup Growth
VEGF is important to Müller cell health and neuroprotec-
tion.13,23,24 Therefore, we tested whether shRNAs to either
FIGURE 3. Lentivector-derived shRNA to VEGFA or VEGF164 reduces IVNV without affecting physiological retinal vascular development (AVA) in the
rat ROP model. Images of retinal flatmounts at P18 and P25 following subretinal injections in each group. (A) luc.shRNA, VEGFA.shRNA, and
VEGF164.shRNA. *Points to avascular retinal area. A white arrow points to IVNV. (B) Quantification of IVNV. *P < 0.05. ***P < 0.001 versus
luc.shRNA at P8. †P < 0.01 versus VEGFA.shRNA at P25. ###P < 0.001 versus VEGFA.shRNA at P18. (C) Avascular retina.
FIGURE 4. Analysis of VEGFR2 activation in pups treated with subretinal injections of lentivector-driven shRNAs in the rat ROP model. (A)
Immunohistochemistry of p-VEGFR2 in retinal cryosections. (B) Semiquantification of p-VEGFR2 (blue) in total retina (***P < 0.001 versus
luc.shRNA at P25). (C) Colabeling of p-VEGFR2 (blue) in lectin (red)-labeled ECs in the primary plexus (depicted within boxes; *P < 0.05, **P < 0.01
versus luc.shRNA at P18; ††P< 0.01 versus luc.shRNA at P25) from P18 and P25 pups treated with luc.shRNA, VEGFA.shRNA, and VEGF164.shRNA.
Inhibition of Müller Cell–Derived VEGF164 on IVNV IOVS j February 2014 j Vol. 55 j No. 2 j 828
VEGFA or VEGF164 affected retinal cell survival at P18 or P25
by assessing TUNEL staining (Fig. 5A). Compared with PBS,
luciferase.shRNA increased TUNELþ cells at P18 but not at P25
(Fig. 5B). Although we previously found VEGFA knockdown
did not increase apoptosis in P18 retinal lysates,12 sections
from VEGFA.shRNA, but not VEGF164.shRNA treated eyes had
significantly increased TUNELþ cells in both INL and ONL
compared with luciferase.shRNA at P18. At P25, TUNELþ cells
were significantly reduced compared with respective groups at
P18, and there were no significant differences in TUNELþ cells
among the groups at P25. Compared with PBS, luciferase.shR-
NA treatment did not alter the thickness of the retina (data not
shown), the INL (Fig. 5C) or ONL (Fig. 5D). However, eyes
treated with the VEGFA.shRNA had significantly reduced ONL
thickness compared with luciferase.shRNA at both P18 and
P25 (Fig. 5D). Compared with luciferase.shRNA, no differences
in thickness of total retina at P18 or P25 (data not shown) or
INL at P18 were detected after VEGFA.shRNA or VEGF164.shR-
NA injections (Fig. 5C). At P25, the INL was thicker in the
VEGF164.shRNA group than the other groups (Fig. 5C).
Subretinal VEGFA.shRNA or VEGF164.shRNA did not affect
body weight gain (Fig. 6A) or serum VEGF (Fig. 6B) compared
with luciferase.shRNA at either time point.
DISCUSSION
We provide evidence that targeting Müller cells with an shRNA
to one splice variant of VEGF, VEGF164, was safer and more
effective at inhibiting and maintaining inhibition of IVNV than
targeting all splice variants of VEGFA in a rat model
representative of human ROP. We chose to target Müller cells,
because we found that VEGF–splice variant mRNAs localized to
cells in the INL corresponding to CRALBP-labeled Müller cells
and that knockdown of VEGFA in Müller cells inhibited IVNV at
the early time point, P18.12 Previously, Bai et al.25 found that
Müller cell-expressed VEGF was important in causing IVNV by
developing and testing a Müller cell conditional VEGF
knockout in the mouse OIR model. Our study not only differs
by testing long-term safety and comparing knockdown of a
Müller cell-expressed splice variant—VEGF164—to knockdown
of Müller cell-VEGFA, but also studies the rat OIR model, which
FIGURE 5. Analysis of retinal apoptosis and retinal morphological changes in the pups treated with lentivector-driven shRNAs in the rat ROP model.
Images of TUNEL staining (A) and number of TUNEL (red) positive cells (B) in retinal DAPI (blue) stained cryosections from P18 and P25 pups
treated with luc.shRNA, VEGFA.shRNA, and VEGF164.shRNA (**P < 0.01, ***P < 0.001 versus PBS at P18; †††P < 0.001 versus luc.shRNA at P18).
Quantification of the thickness of the INL (C) (***P < 0.001 versus PBS at P18; ††P < 0.01 versus luc.shRNA at P25) and the ONL (D) (***P < 0.001
versus luc.shRNA at P18; ††P < 0.001 versus luc.shRNA at P25) in DAPI-stained retinal cryosections from P18 and P25 OIR pups treated with
luciferase.shRNA, VEGFA.shRNA, and VEGF164.shRNA.
FIGURE 6. Lentivector-driven shRNAs treatment has no effect on pup growth and serum VEGF. Pup weight gains from P8 to P18 or P25 (A) and
ELISA of serum VEGF in P18 or P25 pups (B) treated with luc.shRNA, VEGFA.shRNA, and VEGF164.shRNA in the rat ROP model.
Inhibition of Müller Cell–Derived VEGF164 on IVNV IOVS j February 2014 j Vol. 55 j No. 2 j 829
is a representative model of human ROP in places where
oxygen is regulated.26
Studies in human preterm infants show that IVNV can recur
following anti-VEGF treatments.27–29 Experimentally, broad
inhibition of VEGF with an intravitreal neutralizing antibody
led to upregulation of angiogenic compounds in association
with recurrent IVNV.9 We hypothesized that inhibition of all
VEGF splice variants would affect both pathologic and
physiologic processes and lead to cell death or compensatory
upregulation of angiogenic pathways. Therefore, we targeted
one splice variant of VEGF to inhibit pathologic angiogenesis
and potentially preserve physiologic effects from VEGF. We
chose VEGF164 based on the finding that of the three rat splice
variants of VEGFA (VEGF120, VEGF164, and VEGF188), VEGF164
was the most prevalent10,30 and unlike VEGF120 or VEGF188,
was increased in association with both older developmental
age and the ROP model compared with RA.10 We also found
that VEGF164 was upregulated by repeated fluctuations in
oxygenation, whereas VEGF120 was upregulated by hypoxia
alone.30 Physiologic events can be stimulated by hypoxia
alone.31 Also, evidence is accumulating that fluctuations in
oxygenation are important in ROP.32,33 Others have reported
VEGF164 as the splice variant most likely to cause inflammation
and abnormal angiogenesis.14 For all these reasons, we
compared the efficacy and safety of targeting Müller cell-
VEGF164 or -VEGFA with shRNAs in the rat model of ROP. We
chose a lentivector because lentivirus is incorporated into the
genome and provides a robust means to study VEGF
knockdown longitudinally.
Although we found that targeting VEGF164 with shRNA was
more effective at maintaining inhibition of IVNV than targeting
VEGFA, we cannot directly compare the two. The shRNA to
VEGFA had greater knockdown in HEK164 reporter cell lines
than did VEGF164-specific shRNA, which was selective to
VEGF164 and not VEGF120. Therefore, the dose effect of
VEGF164.shRNA in Müller cells may account for some of the
outcomes we found. For example, there was greater knock-
down of VEGF in P18 retinal lysates from eyes treated with
VEGFA.shRNA than with VEGF164.shRNA; but after a longer
time for lentiviral transduction, VEGF164.shRNA treatment
reduced VEGF in P25 retinal lysates similar to VEGFA.shRNA.
VEGF120, which was not knocked down by VEGF164.shRNA,
has soluble properties enabling it to move to other cells within
the retina, and may have accounted for the lack of cell death
and increased INL thickness noted in P25 sections from eyes
treated with VEGF164.shRNA.
Based on densitometry of labeled retinal sections, knock-
down of VEGF164 or VEGFA had no effect on overall retinal
VEGFR2 activation at P18; but at a later time point, both
VEGFA.shRNA and VEGF164.shRNA each led to greater retinal
p-VEGFR2. This suggests a compensatory increase in VEGFR2
activation. One explanation may be upregulation of VEGF in
other cells in the retina. However, we did not find evidence of
increased retinal VEGF at P25. The ELISA technique measures
only unbound VEGF and may miss VEGF bound to VEGFR.34
We previously found that Müller cell-VEGF activates endothelial
cell VEGFR2.12,35 Therefore, to detect differences in p-VEGFR2
among the groups, we used a semiquantitative approach with
densitometry of labeled retinal sections for endothelial cell p-
VEGFR2. This method showed reduced p-VEGFR2 densitome-
try in ECs at P18, but increased p-VEGFR2 in ECs at P25 retinas
that had been treated with the VEGFA.shRNA, not
VEGF164.shRNA, and in association with an increase in IVNV
at P25, suggesting compensatory signaling effects.
In a previous publication12 and confirmed here, targeted
knockdown of overexpressed VEGFA in Müller cells reduced
IVNV at P18 without adversely affecting body weight gain or
causing apoptosis measured as cleaved caspase-3 in retinal
lysates.9 Here, using TUNEL, we found VEGFA knockdown
caused more cell death compared with luciferase.shRNA
treatment. This may be because TUNEL does not discriminate
apoptosis from necrosis and that the sensitivity in detecting a
small group of cells undergoing apoptosis was insufficient
using Western analysis of whole retinal lysates. At P25, there
was no difference in TUNELþ cells, suggesting absence of
ongoing cell death. However, VEGFA.shRNA also reduced ONL
thickness at P25. Müller cells require VEGF for their own
survival13 and produce VEGF and other factors important to
retinal neuronal survival,28,29 including photoreceptors whose
nuclei reside in the ONL. Conditional knockout of Müller cells
in a mouse model led to photoreceptor degeneration.36 Future
studies of the effects of long-term knockdown of Müller cell-
VEGF such as through electrophysiology and spectral domain
optical coherence tomography are warranted.
In summary, knockdown of splice variant, VEGF164, in
Müller cells appears safer and more effective in inhibiting IVNV
in the long-term than targeted knockdown of VEGFA,
suggesting that maintaining the expression of some splice
variants of VEGFA may improve survival of cells within the
retina. Additional studies regarding potential compensatory
signaling of Müller cells after VEGF inhibition and on long-term
structure and function from knockdown of VEGFA or VEGF164
are warranted. Effects of VEGF knockdown on endothelial
effectors are also important to determine.
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